These multi-level results, from molecular interactions to cellular phenotypes, collectively demonstrate that abemaciclib specifically targets HOXC6, forms stable complexes, and significantly inhibits colorectal cancer cell proliferation, migration, and invasion capabilities. This evidence concerns the gene HOXC6 and colorectal cancer.